Read the full Instructions for Use.
Not actual size. Keep HYMPAVZI pen out of direct sunlight.
Not an actual patient.
For routine prophylaxis in patients 12 years and older with hemophilia A or B without inhibitors
Only HYMPAVZI is a once-weekly fixed-dose* pen with proven bleed protection† and demonstrated safety‡
The same dose comes in every pen, so you don't need to mix or measure
Once-weekly dosing designed to fit into your schedule
Injected under the skin, not into a vein
*Your first dose (loading dose) of HYMPAVZI is 300 mg (two 150 mg injections). Then you will inject a weekly (maintenance) dose consisting of 1 or 2 injections as prescribed by your healthcare provider. If more than 1 injection is required to deliver a complete dose, administer each injection at a different injection site.
†92% reduction in treated bleeds on HYMPAVZI compared to on-demand factor-based treatment (3.20 annualized bleed rate [ABR] vs 39.86 ABR). 36% reduction in treated bleeds on HYMPAVZI compared to routine factor-based prophylaxis treatment (5.09 ABR vs 7.90 ABR).
‡In the BASIS Study, the most common adverse reactions included injection site reactions, headache, and pruritus.
Proven bleed protection with HYMPAVZI§
Treated bleeds
Joint bleeds
Target joint bleeds
Spontaneous bleeds
Total bleeds
compared to on-demand factor-based treatment and prophylactic factor-based treatment
§In the BASIS phase 3 study, the primary objective was to measure the annualized bleed rate (ABR) of treated bleeds vs on-demand factor-based treatment and vs factor-based prophylaxis after 12 months on HYMPAVZI. 92% reduction in treated bleeds on HYMPAVZI compared with on-demand factor-based treatment (3.18 ABR vs 38.00 ABR). 35% reduction in treated bleeds on HYMPAVZI compared with routine prophylaxis treatment (5.08 ABR vs 7.85 ABR). Secondary objectives measured the ABR of treated joint bleeds, treated target joint bleeds, treated spontaneous bleeds, and total bleeds (treated and untreated). 91% reduction in joint bleeds on HYMPAVZI compared with on-demand factor-based treatment (2.83 ABR vs 32.86 ABR). 27% reduction in joint bleeds on HYMPAVZI compared with routine prophylaxis treatment (4.13 ABR vs 5.66 ABR). 92% reduction in target joint bleeds on HYMPAVZI compared with on-demand factor-based treatment (1.84 ABR vs 23.18 ABR). 25% reduction in target joint bleeds on HYMPAVZI compared with routine prophylaxis treatment (2.51 ABR vs 3.36 ABR). 92% reduction in spontaneous bleeds on HYMPAVZI compared with on-demand factor-based treatment (2.44 vs 30.93 ABR). 35% reduction in spontaneous bleeds on HYMPAVZI compared with routine prophylaxis treatment (3.78 ABR vs 5.86). 85% reduction in total bleeds on HYMPAVZI compared with on-demand factor-based treatment (7.39 ABR vs 47.76 ABR). 32% reduction in total bleeds on HYMPAVZI compared with routine prophylaxis treatment (5.97 ABR vs 8.84 ABR). Individual results may vary.
Understanding novel non-factor treatment options
Download for details about HYMPAVZI and other approved non-factor prophylactic hemophilia treatments.
Real patient story
Meet Peter and see how once-weekly HYMPAVZI fits into his lifestyle.
Savings program
You may pay as little as $0 for HYMPAVZI if you have commercial insurance and meet the eligibility requirements.¶
¶Eligibility required. Individual savings limited to $15,000 in maximum total savings per calendar year. Only for use with commercial insurance. If you are enrolled in a state or federally funded prescription insurance program, you may not use the savings card. Terms and conditions apply.
Want the lowdown on HYMPAVZI?
Sign up for more information, including educational tools and updates
